Revenue

A new partnership aims to fix the broken music industry with a global commerce engine and advanced AI, giving artists true ownership of their careers.

Why a top security leader's move from a tech giant to a specialized firm signals a major shift in the fight for digital resilience. A deep dive.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

A top FinTech firm's new product chief reveals a strategic roadmap for taming complexity that the defense and space sectors cannot afford to ignore.

Beyond e-commerce, GigaCloud's massive new NJ facility signals a strategic move to fortify trans-pacific supply lines for large goods, impacting US economic competitiveness.

How a social media-fueled cosmetics brand leveraged its whimsical aesthetic to land a major deal with Ulta, rewriting the playbook for digital-first success.

New data shows flat 2026 raises for healthcare workers and a strategic pay gap, while AI's promised workforce revolution is still waiting in the wings.

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

With a $140M war chest, Empower Semiconductor expands to Silicon Valley and Munich, betting its vertical power tech can solve the energy crisis facing AI.

A new project blends blockchain and next-gen security protocols to build a sovereign internet, fortifying Canada's Arctic defense and digital independence.

Amidst a nuclear renaissance, Global Uranium’s detailed mapping in Wyoming de-risks a key project, setting the stage for a critical 2026 drill program.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

After a financial tightrope walk, Actelis Networks is back in Nasdaq's good graces. But the real story is its mission to secure our future's IoT.

Wealth Enhancement's $2.2B deal for L.M. Kohn isn't just another acquisition. It signals a tech-fueled consolidation wave reshaping financial advice.

A new report on AI in the energy sector reveals a critical truth for medicine: general-purpose AI is not ready for high-stakes decisions without human experts.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

A decade-long initiative by Sands China has funneled MOP 119.4B into local businesses, revealing a strategic blueprint for economic diversification.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.